- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03729622
Carbohydrate Reduction and Impact on Gastrointestinal System (CRAIGS)
A Pilot Randomised Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Gastrointestinal Form and Symptoms in Irritable Bowel Syndrome Patients
Title :
A pilot single blind randomised controlled trial of the effect of a diet low in poorly digested carbohydrates on gastrointestinal form and symptoms in irritable bowel syndrome patients
Acronym: CRAIGS
Short title: Carbohydrate reduction and impact on gastrointestinal system Chief Investigator: Prof Robin Spiller
Objectives:
The purpose of this study is to:
- Investigate the proportion of patients with Irritable Bowel Syndrome who report moderate or substantial improvement in their symptoms after 2 weeks of following a diet low in Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs) compared to patients who are on their habitual diet.
- Determine the difference in colonic volume of IBS patients receiving immediate low FODMAP dietary intervention after 2 weeks compared to patients who are not on the diet (delayed dietary intervention).
- Investigate the changes in self-reported food intolerance that occurs before dietary intervention.
Trial Configuration:
2-arm, parallel group, randomised, controlled trial
Setting :
Research clinic within NIHR Biomedical Research Unit, Secondary care
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
TRIAL / STUDY OBJECTIVES AND PURPOSE
The trial aims to investigate the effect of a diet low in FODMAPs on colonic morphology as well as in improving symptoms of irritable bowel syndrome (IBS).
This mechanistic information, along with the clinical data, will allow planning of larger, multi-centre studies of the low FODMAP diet in similar patients.
HYPOTHESES
- Patients on a low FODMAP diet for 2 weeks will have a decreased fasting colonic volume measured by Magnetic Resonance Imaging (MRI) compared to participants who have not started the diet.
- Patients with IBS are more likely to report a clinically important improvement in symptoms following the low FODMAP diet (immediate intervention) compared to those on their habitual diet (delayed intervention).
PRIMARY OBJECTIVE • To compare the proportion of IBS patients reporting a clinically important improvement in symptoms following a low FODMAP diet for 2 weeks against IBS patients who are on their habitual diet.
SECONDARY OBJECTIVES
• Determine the difference in fasting colonic volume of IBS patients receiving low FODMAP dietary intervention after 2 weeks compared to those on habitual diet.
TRIAL DESIGN
This will be a pilot single-blind, randomised, controlled trial (RCT). Since some activity will take place on the University of Nottingham this will be a multi-centre study.
All participants will receive advice from a dietitian on the low FODMAP diet. They will be randomised to one of two parallel treatment arms:
- Low FODMAP dietary advice (immediate intervention)
- Habitual diet (control - delayed intervention )
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Det Forenede Kongerige, NG7 2UH
- Nottingham Digestive Diseases Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion Criteria:
Inclusion
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion
- Children (<18 years)
History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to:
- Inflammatory Bowel Disease
- Coeliac Disease
- Pancreatitis
- Gallstone disease (biliary colic, cholecystitis)
- Diverticulitis
- Cancer of the gastrointestinal tract
- Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder
- Intestinal stoma
- Limited understanding of English
- Pregnancy declared by the candidate
- Red flag symptoms such as rectal bleeding, family history of bowel or ovarian cancer, a change in bowel habit to looser and/or more frequent stools persisting for more than six weeks in a person aged over 60 years.
- Investigations showing positive tissue transglutaminase (tTG) IgA antibodies
- Anaemia confirmed by full blood count test
- Habitual use of opiate analgesics likely to alter bowel function e.g. morphine
- Use of antibiotics in the preceding four weeks other than for treatment of index infection.
- Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration
- Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting memory and understanding
- Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. chaotic lifestyle related to substance abuse
- Dietary practice not compatible with safe implementation of the trial diet e.g.veganism
- Medical reasons for pre-existing controlled diet that cannot be safely randomised e.g. end-stage kidney disease, diabetes
- Participants taking prebiotic/probiotic
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Immediate Intervention
Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
Placebo komparator: Delayed Intervention
Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Adequate symptom relief between cases and controls
Tidsramme: Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Adequate symptom relief assessed by questionnaire after intervention in cases and before intervention in cases
|
Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in colonic volume between cases and controls from baseline
Tidsramme: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in colonic volume measured in milliliters (ml) from baseline and after intervention in cases.
This will compared with a change in colonic volume from baseline and before intervention in controls.
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
Changes in fermentation between cases and controls
Tidsramme: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in breath hydrogen concentration measured in parts per million (ppm) from: baseline and after intervention (cases) ii) from baseline and before intervention (controls)
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 15081
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Irritabelt tarmsyndrom
-
Seoul National University HospitalUkendtSund og rask | Kronisk forstoppelse | Constipated Irritable Bowel Syndrome
-
Hacettepe UniversityAfsluttetKolorektal cancer | Ammende | Koloskopi forberedelse | Boston Bowel Preparation ScaleKalkun
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
Kliniske forsøg med Low FODMAP Diet
-
Advocate Health CareTrukket tilbageDyspepsi | KostændringerForenede Stater
-
Ashok TutejaUnited States Department of DefenseUkendt
-
Karolinska InstitutetAleris Gastromottagningen CityIkke rekrutterer endnu
-
Medical University of WarsawNutricia FoundationUkendt
-
University of SuffolkRekrutteringIrritabelt tarmsyndrom | Fødevareintolerance | Funktionel tarmsygdom | Fødevareintolerance syndromerDet Forenede Kongerige
-
Northwestern UniversityTrukket tilbage
-
Jens Rikardt AndersenAfsluttet
-
University of MinnesotaAfsluttetUdvalg af madForenede Stater
-
Baylor College of MedicineUniversity of WashingtonRekrutteringForudsiger biomarkører reaktion på et pædiatrisk program til behandling af kroniske smertesymptomer?Irritabelt tarmsyndrom | Funktionelle mavesmerter | Funktionelle gastrointestinale lidelser | Funktionelt abdominalt smertesyndrom | Funktionel tarmsygdom | Funktionelle mavesmerterForenede Stater
-
Cantonal Hospital of St. GallenAfsluttetIBS - Irritabel tyktarm